CA-ASM-GLOBAL
ASM Global, the world’s leading venue management company and producer of live experiences, has partnered with the Malaysian Ministry of Youth and Sports via Perbadanan Stadium Malaysia (PSM) to enhance existing operations and event activity at the Kuala Lumpur Sports City precinct, the largest sports complex in the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005375/en/
The announcement is a further step forward in the Malaysian government’s ambition to see the National Sports Precinct at Bukit Jalil develop a world-class reputation as the host of leading sports, entertainment and community events. It also expands ASM Global’s footprint in Asia with the addition of an iconic sports and events precinct, including the 87,400-seat Malaysia National Stadium.
The Malaysia National Stadium is not only the largest stadium in Asia outside North Korea, it is now the largest stadium in ASM Global’s worldwide collection.
ASM Global brings its vast industry experience in redefining the guest journey, implementing the latest technology, elevating F&B offerings, and the advantage of a regionally based team together with its commercial venue know-how, wide ranging event network and technical capabilities.
ASM Global President and CEO Ron Bension said, “We’re on a robust growth curve in this part of the world. The Kuala Lumpur Sports City precinct is representative of the types of projects we’re championing that significantly enrich the venue benefits and utilize our vast international expertise and best practices.”
Chairman and Chief Executive of ASM Global Asia Pacific and Gulf Region Harvey Lister AM said the group was delighted to be partnering with the management team at the iconic Kuala Lumpur Sports City in a joint endeavor to further establish the precinct as a vibrant community and event hub for the people of Malaysia.
“We firmly believe the Malaysia National Stadium and the Axiata Arena have the potential expressed by the Malaysia Sports Ministry, and we are proud to welcome the local teams and venues into our network of venues and support the precinct in helping deliver more events for the people of Malaysia and the region,” said Lister.
ASM Global will partner with local Malaysian company Sportswork Sdn Bhd in delivering services for Kuala Lumpur Sports City.
Malaysia Sports Minister, Y.B. Dato’ Seri Ahmad Faizal bin Dato’ Azumu, said, “We see this MOU as a great opportunity for PSM and ASM Global to enhance Kuala Lumpur Sports City to a premier destination in the global sports and event industry. Both National Stadium Bukit Jalil and Axiata Arena are iconic properties owned by the Malaysian people, and we owe them a responsibility to ensure these venues make us proud.”
ABOUT ASM GLOBAL
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Follow us on Facebook , Instagram , LinkedIn and Twitter . asmglobal.com
ASM Global’s expanding family of facilities in the Asia Pacific includes the following venues:
- Entertainment and Sports Arenas: Qudos Bank Arena, Sydney; RAC Arena, Perth; Brisbane Entertainment Centre; Newcastle Entertainment Centre; Aware Super Theatre at ICC Sydney; BCEC Great Hall, Brisbane; Cairns Arena: Bangkok Arena and EM Live Theatre, Bangkok (under development), Coca Cola Arena, Dubai; Kai Tak Indoor Arena, Hong Kong; and Jeddah Arena, Saudi Arabia (under development).
- Live Performance Theatres: Brisbane, Cairns, Darwin, Sydney, Kuala Lumpur and Bahrain.
- Convention and Exhibition Centres: Brisbane, Cairns, Darwin, Newcastle, Sydney, Christchurch, Kuala Lumpur, Shenzhen, Bahrain (under construction) and Jeddah (under development).
- Stadiums: Suncorp Stadium in Brisbane; Kai Tak Sports Park, Hong Kong (under construction); a significant ownership of VenuesLive, the operator of Stadium Australia, Sydney; CommBank Stadium, Parramatta; Optus Stadium, Perth, and service provider to WIN Stadium, Wollongong; McDonald Jones Stadium, Newcastle; Netstrata Jubilee Stadium, Sydney; and Central Coast Stadium, Gosford.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005375/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom